Annual accounts receivable:
$1.61B+$46.00M(+2.94%)Summary
- As of today (June 14, 2025), VRTX annual accounts receivable is $1.61 billion, with the most recent change of +$46.00 million (+2.94%) on December 31, 2024.
- During the last 3 years, VRTX annual accounts receivable has risen by +$472.60 million (+41.57%).
- VRTX annual accounts receivable is now at all-time high.
Performance
VRTX Accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly accounts receivable:
$1.81B+$195.70M(+12.16%)Summary
- As of today (June 14, 2025), VRTX quarterly accounts receivable is $1.81 billion, with the most recent change of +$195.70 million (+12.16%) on March 31, 2025.
- Over the past year, VRTX quarterly accounts receivable has increased by +$11.90 million (+0.66%).
- VRTX quarterly accounts receivable is now at all-time high.
Performance
VRTX Quarterly accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Accounts receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
VRTX Accounts receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +2.9% | +0.7% |
| 3 y3 years | +41.6% | +39.6% |
| 5 y5 years | +154.0% | +113.5% |
VRTX Accounts receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +41.6% | at high | +39.6% |
| 5 y | 5-year | at high | +154.0% | at high | +128.0% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% |
VRTX Accounts receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $1.81B(+12.2%) |
| Dec 2024 | $1.61B(+2.9%) | $1.61B(-8.1%) |
| Sep 2024 | - | $1.75B(+5.7%) |
| Jun 2024 | - | $1.66B(-7.6%) |
| Mar 2024 | - | $1.79B(+14.7%) |
| Dec 2023 | $1.56B(+8.4%) | $1.56B(+1.6%) |
| Sep 2023 | - | $1.54B(-1.1%) |
| Jun 2023 | - | $1.56B(+0.5%) |
| Mar 2023 | - | $1.55B(+7.3%) |
| Dec 2022 | $1.44B(+26.9%) | $1.44B(+4.1%) |
| Sep 2022 | - | $1.39B(+3.9%) |
| Jun 2022 | - | $1.33B(+3.1%) |
| Mar 2022 | - | $1.29B(+13.7%) |
| Dec 2021 | $1.14B(+28.4%) | $1.14B(+3.3%) |
| Sep 2021 | - | $1.10B(+18.4%) |
| Jun 2021 | - | $929.14M(-5.0%) |
| Mar 2021 | - | $977.55M(+10.4%) |
| Dec 2020 | $885.40M(+39.8%) | $885.40M(+11.8%) |
| Sep 2020 | - | $791.92M(+0.0%) |
| Jun 2020 | - | $791.77M(-6.3%) |
| Mar 2020 | - | $845.27M(+33.4%) |
| Dec 2019 | $633.52M(+54.6%) | $633.52M(+42.9%) |
| Sep 2019 | - | $443.31M(-4.6%) |
| Jun 2019 | - | $464.90M(+6.1%) |
| Mar 2019 | - | $438.30M(+7.0%) |
| Dec 2018 | $409.69M(+45.6%) | $409.69M(+7.9%) |
| Sep 2018 | - | $379.75M(-3.5%) |
| Jun 2018 | - | $393.44M(+20.2%) |
| Mar 2018 | - | $327.29M(+16.3%) |
| Dec 2017 | $281.34M(+40.4%) | $281.34M(+6.8%) |
| Sep 2017 | - | $263.49M(+6.3%) |
| Jun 2017 | - | $247.95M(+19.2%) |
| Mar 2017 | - | $207.96M(+3.8%) |
| Dec 2016 | $200.36M(+15.3%) | $200.36M(+10.0%) |
| Sep 2016 | - | $182.23M(-3.8%) |
| Jun 2016 | - | $189.36M(+4.1%) |
| Mar 2016 | - | $181.88M(+4.6%) |
| Dec 2015 | $173.84M(+128.8%) | $173.84M(+5.2%) |
| Sep 2015 | - | $165.27M(+74.9%) |
| Jun 2015 | - | $94.52M(+17.7%) |
| Mar 2015 | - | $80.33M(+5.8%) |
| Dec 2014 | $75.96M(-11.2%) | $75.96M(-33.5%) |
| Sep 2014 | - | $114.31M(+39.7%) |
| Jun 2014 | - | $81.84M(+36.7%) |
| Mar 2014 | - | $59.86M(-30.0%) |
| Dec 2013 | $85.52M(-40.3%) | $85.52M(-28.9%) |
| Sep 2013 | - | $120.28M(-27.0%) |
| Jun 2013 | - | $164.87M(-15.0%) |
| Mar 2013 | - | $194.05M(+35.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2012 | $143.25M(-21.8%) | $143.25M(+2.6%) |
| Sep 2012 | - | $139.63M(-24.8%) |
| Jun 2012 | - | $185.62M(-20.1%) |
| Mar 2012 | - | $232.23M(+26.8%) |
| Dec 2011 | $183.13M(+1361.7%) | $183.13M(-58.9%) |
| Sep 2011 | - | $445.66M(+364.2%) |
| Jun 2011 | - | $96.02M(+1616.4%) |
| Mar 2011 | - | $5.59M(-55.4%) |
| Dec 2010 | $12.53M(+30.5%) | $12.53M(+152.4%) |
| Sep 2010 | - | $4.96M(+39.9%) |
| Jun 2010 | - | $3.55M(-55.0%) |
| Mar 2010 | - | $7.88M(-18.0%) |
| Dec 2009 | $9.60M(-59.1%) | $9.60M(-5.6%) |
| Sep 2009 | - | $10.17M(-31.1%) |
| Jun 2009 | - | $14.76M(-11.6%) |
| Mar 2009 | - | $16.70M(-28.9%) |
| Dec 2008 | $23.49M(-25.0%) | $23.49M(+6.9%) |
| Sep 2008 | - | $21.97M(+43.0%) |
| Jun 2008 | - | $15.37M(-38.1%) |
| Mar 2008 | - | $24.82M(-20.7%) |
| Dec 2007 | $31.32M(-50.2%) | $31.32M(-9.6%) |
| Sep 2007 | - | $34.66M(-6.8%) |
| Jun 2007 | - | $37.19M(-15.7%) |
| Mar 2007 | - | $44.10M(-29.9%) |
| Dec 2006 | $62.92M(+205.5%) | $62.92M(+47.7%) |
| Sep 2006 | - | $42.61M(-76.8%) |
| Jun 2006 | - | $183.67M(+672.4%) |
| Mar 2006 | - | $23.78M(+15.5%) |
| Dec 2005 | $20.59M(+73.2%) | $20.59M(-0.8%) |
| Sep 2005 | - | $20.76M(+48.9%) |
| Jun 2005 | - | $13.94M(+28.3%) |
| Mar 2005 | - | $10.87M(-8.6%) |
| Dec 2004 | $11.89M(+62.4%) | $11.89M(+40.2%) |
| Sep 2004 | - | $8.48M(-14.7%) |
| Jun 2004 | - | $9.94M(+25.2%) |
| Mar 2004 | - | $7.94M(+8.4%) |
| Dec 2003 | $7.32M(-44.5%) | $7.32M(-6.7%) |
| Sep 2003 | - | $7.85M(-19.2%) |
| Jun 2003 | - | $9.72M(-18.5%) |
| Mar 2003 | - | $11.93M(-9.7%) |
| Dec 2002 | $13.20M(-34.9%) | $13.20M(+0.8%) |
| Sep 2002 | - | $13.10M(-27.4%) |
| Jun 2002 | - | $18.06M(+25.9%) |
| Mar 2002 | - | $14.34M(-29.2%) |
| Dec 2001 | $20.27M(-40.2%) | $20.27M(-43.6%) |
| Sep 2001 | - | $35.92M(+327.0%) |
| Jun 2001 | - | $8.41M(+10.5%) |
| Mar 2001 | - | $7.62M(-77.5%) |
| Dec 2000 | $33.91M(+469.3%) | $33.91M(+469.3%) |
| Dec 1999 | $5.96M | $5.96M |
FAQ
- What is Vertex Pharmaceuticals Incorporated annual accounts receivable?
- What is the all time high annual accounts receivable for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated annual accounts receivable year-on-year change?
- What is Vertex Pharmaceuticals Incorporated quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated quarterly accounts receivable year-on-year change?
What is Vertex Pharmaceuticals Incorporated annual accounts receivable?
The current annual accounts receivable of VRTX is $1.61B
What is the all time high annual accounts receivable for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high annual accounts receivable is $1.61B
What is Vertex Pharmaceuticals Incorporated annual accounts receivable year-on-year change?
Over the past year, VRTX annual accounts receivable has changed by +$46.00M (+2.94%)
What is Vertex Pharmaceuticals Incorporated quarterly accounts receivable?
The current quarterly accounts receivable of VRTX is $1.81B
What is the all time high quarterly accounts receivable for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high quarterly accounts receivable is $1.81B
What is Vertex Pharmaceuticals Incorporated quarterly accounts receivable year-on-year change?
Over the past year, VRTX quarterly accounts receivable has changed by +$11.90M (+0.66%)